济南医院如何查前列腺(济南早泻能治) (今日更新中)

BEIJING, Oct. 27 (Xinhuanet) -- Virginia M. Rometty, 54, will succeed present IBM CEO Sam Palmisano to be the next chief executive at the start of 2012, the company announced Tuesday.This is unprecedented in the New York-based company's 100-year history, because Rometty, a senior vice president of IBM, will be its first female CEO.Since joining the company three decades ago, Ms. Rometty has contributed a lot to the giant I.T. Company.After graduating from Northwestern University with an undergraduate degree in computer science, she entered the company in 1981 as a systems engineer. In virtue of outstanding performance, she was quickly promoted to management.For the following 20 years, she worked with clients in banking, insurance, and telecommunications, to name a few.In 2002, Rometty caught Palmisano's attention when she helped integrate the 3.5 billion dollar acquisition of the big business consulting firm PricewaterhouseCoopers Consulting, IBM's largest deal ever at the time.Then she became senior vice president of the group and group executive for sales, marketing and strategy in 2009. Under her leading, the business in overseas emerging markets including China, India, Brazil and several African nations, has increased sharply.New York Times reported that such markets now accounted for 23 percent of IBM.’s revenue, up from 20 percent when she took over.“Ginni got it because she deserved it,” Mr. Palmisano told the New York Times. "Ginni" is an informal first name used by her friends and colleagues.The selection of Rometty for chief executive will make her the 17th female CEO in the Fortune 500 on the following January. Other prominent women who play the same role as Rometty include Indra Nooyi of PepsiCo, Ellen J. Kullman of DuPont, Meg Whitman of Hewlett-Packard, and so on.

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.

BEIJING, Oct. 14 (Xinhuanet) -- Materialism could be harmful to marriage, according to a new study published in the American Journal of Couple & Relationship Therapy Thursday.The researchers collected online "relationship assessment" questionnaires from 1,734 U.S. married couples.The questionnaire covered the topics about the couples' marital satisfaction, conflict patterns, marital communication, and marriage stability, and so on.Non-materialistic couples were about 10 to 15 percent better than those materialistics in their marital satisfaction, marriage stability and conflict levels, according to the study."What we found was a general pattern that materialism seems to be harmful to marriage," said study researcher Jason Carroll, a professor of family life at Brigham Young University.It didn't matter whether the materialistic spouse was the man or the woman, he added.However, materialism is not simply black-or-white: some couples can pursue their fortune and keep their relationship strong at the same time, the researcher suggested.But breaking their materialistic thought would be helpful for most couples, Carroll concluded.

WASHINGTON, Dec. 7 (Xinhua) -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.Their report, published on-line Wednesday in Gynecologic Oncology, suggests that this combination, ixabepilone and sunitinib, might offer a much needed treatment option for women with advanced ovarian cancer.Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it."Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance -- which may be what this combination of agents is doing -- would be a boon to treatment of this difficult cancer," says study coauthor Gerardo Colon-Otero.The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. It might be a potential biomarker that may help identify patients who might benefit from such combination therapy, the researchers say.

WASHINGTON, Nov. 16 (Xinhua) -- Supervised exercise was shown to be more effective than stenting or medication for improved walking ability in patients with peripheral artery disease (PAD), according to a U.S. study reported Wednesday at the 2011 American Heart Association Scientific Sessions meeting.The research group reported that of 111 patients studied in the randomized trial, the most effective treatment proved to be supervised exercise based on the results of a treadmill test taken at baseline and again at six months. Patients who were in the supervised exercise group improved by a mean of 4.6 minutes in the treadmill test, while the group who received stents improved by a mean of 2.5 minutes. However, researchers found that self-reported quality of life measurements proved to be higher in the group that received stents, even though their ability to walk did not improve as greatly as the group that received supervised exercise rehabilitation.The findings were published in the November issue of the journal Circulation. The researchers believe that more studies are necessary, although supervised exercise may be an effective treatment recommended for PAD patients with claudication.PAD is a condition in which plaque builds up in the arteries and affects blood flow, especially to the legs. It is estimated that between 10 and 12 million people suffer from PAD in the United States. One symptom of PAD is known as claudication, a painful cramping of the leg muscles that limits the patient's ability to walk. It affects nearly 2 million people who suffer from PAD, and results in a sedentary lifestyle and poor quality of life.Current U.S. guidelines for the treatment of claudication include pharmacotherapy, supervised exercise rehabilitation and lower extremity revascularization using stents.

来源：资阳报